Remeditex Ventures
Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential.
Business Model:
Revenue: $7.3M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Remeditex Ventures Information
Geographic Data
Address: 2101 Cedar Springs Rd
City: Dallas
State: TX
Zip: 75201
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
Contact Phone:
+12145062662
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2015 | Viridian Therapeutics | Series B | 0 |
| 4/2012 | Viridian Therapeutics | Series B | 20M |
| 11/2015 | Viridian Therapeutics | Series C | 0 |
| 3/2012 | Bellicum Pharmaceuticals | Series B | 20M |
| 7/2011 | Peloton Therapeutics | Series A | 18M |
| 5/2015 | VYNE Therapeutics | Series A | 14.3M |
| 9/2017 | Rodin Therapeutics | Series C | 0 |
| 6/2019 | Soliton | Post-IPO Equity | 0 |
| 1/2014 | Bellicum Pharmaceuticals | Series B | 14.7M |
| 9/2016 | Peloton Therapeutics | Series D | 0 |
| 6/2014 | Viridian Therapeutics | Series B | 7M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 2/2012 | Apollo Endosurgery | Series B | 0 |
| 3/2009 | BiOptix Diagnostics | Series A | 3M |
| 9/2012 | Bi02 Medical | Series C | 0 |
| 6/2019 | Soliton | Post-IPO Equity | 0 |
| 9/2017 | Rodin Therapeutics | Series C | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 0 |
| 9/2016 | Peloton Therapeutics | Series D | 0 |
| 12/2015 | Navitor Pharmaceuticals | Series B | 0 |
| 11/2015 | Viridian Therapeutics | Series C | 0 |
| 11/2015 | VYNE Therapeutics | Series B | 0 |
| 5/2015 | VYNE Therapeutics | Series A | 0 |
| 2/2015 | Viridian Therapeutics | Series B | 0 |
| 6/2014 | Viridian Therapeutics | Series B | 0 |
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
